Patents Issued in February 18, 2016
-
Publication number: 20160045505Abstract: The present invention provides compounds of formula (I): (Formula (I)) or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.Type: ApplicationFiled: March 13, 2014Publication date: February 18, 2016Applicant: NOVARTIS AGInventors: Agnes VIDAL, Pranab Kumar MISHRA
-
Publication number: 20160045506Abstract: The present invention relates to a method of treating glioma in a subject. The method comprises selecting a subject having a glioma, providing an inhibitor of binding between a PAR-1 receptor and a ligand of the PAR-1 receptor, and administering the inhibitor to the selected subject under conditions effective to treat the glioma and/or prevent spread of tumor cells. Methods for inhibiting proliferation of glioma cells and/or precursors thereof and a method of screening for compounds suitable for treating glioma in subjects are also disclosed.Type: ApplicationFiled: March 14, 2014Publication date: February 18, 2016Applicant: UNIVERSITY OF ROCHESTERInventors: Steven A. GOLDMAN, Romane AUVERGNE
-
Publication number: 20160045507Abstract: The subject matter generally relates to methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.Type: ApplicationFiled: March 17, 2014Publication date: February 18, 2016Inventor: Lawrence WENNOGLE
-
Publication number: 20160045508Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.Type: ApplicationFiled: August 10, 2015Publication date: February 18, 2016Applicant: Pfizer Inc.Inventors: Michael L. VAZQUEZ, Neelu KAILA, Jamison B. TUTTLE, Patrick Robert VERHOEST, Matthew R. REESE, Karen J. COFFMAN, Tarek SAMAD, James M. DUERR, Simone SCIABOLA, Mihir D. PARIKH
-
Publication number: 20160045509Abstract: This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants.Type: ApplicationFiled: October 29, 2015Publication date: February 18, 2016Applicant: G1 Therapeutics, Inc.Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
-
Publication number: 20160045510Abstract: The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.Type: ApplicationFiled: June 30, 2015Publication date: February 18, 2016Applicant: Mezzion Pharma Co., Ltd.Inventor: James L. Yeager
-
Publication number: 20160045511Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.Type: ApplicationFiled: August 11, 2015Publication date: February 18, 2016Inventors: Peter Brent Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel, Radoslaw Laufer, Guohua Pan
-
Publication number: 20160045512Abstract: The present invention relates inter alia to the treatment or prevention of influenza virus infection (including subtypes influenza A virus, influenza B virus, avian strain H5N1, A/H1N1, H3N2 and/or pandemic influenza) using compounds which inhibit the activity of p59-HCK and to a method of screening for a candidate drug substance intended to prevent or treat influenza virus infection in a subject, said method comprising identifying a test substance capable of inhibiting p59-HCK activity.Type: ApplicationFiled: October 14, 2015Publication date: February 18, 2016Applicant: RESPIVERT LIMITEDInventors: Catherine Elisabeth Charron, Robert Fenton, Scott Crowe, Kazuhiro Ito, Peter Strong, William Garth Rapeport
-
Publication number: 20160045513Abstract: The use of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain, the central nervous system and/or the blood and/or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von Hippel-Lindau syndrome, multicentric Castleman disease and/or psioriasis.Type: ApplicationFiled: October 28, 2015Publication date: February 18, 2016Applicant: Novartis AGInventors: Patrick Chene, Carlos Garcia-Echeverria, Michael Rugaard Jensen, Cornelia Quadt, Thomas Radimerski, Joseph Schoepfer
-
Publication number: 20160045514Abstract: Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.Type: ApplicationFiled: March 13, 2014Publication date: February 18, 2016Applicant: The California Institute for Biomedical ResearchInventors: Peter G. SCHULTZ, Arnab K. CHATTERJEE, Shoutian ZHU, Joshua PAYETTE, Hongchul YOON, Baiyuan YANG
-
Publication number: 20160045515Abstract: Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents.Type: ApplicationFiled: July 6, 2015Publication date: February 18, 2016Applicant: Genentech, Inc.Inventors: Marcia Belvin, Lori Friedman, Deepak Sampath, Jeffrey Wallin
-
Publication number: 20160045516Abstract: The invention provides and describes solid state 17?-ethynyl-androst-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17?-ethynyl-androst-5-ene-3?,7?,17?-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17?-ethynyl-androst-5-ene-3?,7?,17?-triol and uses of such formulations in treating the described conditions.Type: ApplicationFiled: August 14, 2014Publication date: February 18, 2016Applicant: Harbor Therapeutics, Inc.Inventors: Steven K. White, Igor Ivanisevic, Kyle Stephens, Mark Andres, Brenton Skylar Wolfe
-
Publication number: 20160045517Abstract: The present invention relates to the formulations, methods and kits for reducing cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and/or for the inhibition of p38 mitogen activating protein kinase (MAPK) activity involving the use of 17?-hydroxyprogesterone caproate (17-OHPC) or derivatives thereof. The formulation may be in the form of an inhalant containing effective amounts of 17-OHPC, and the formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) with 17-OPHC.Type: ApplicationFiled: September 21, 2015Publication date: February 18, 2016Applicant: PRAIRIE PHARMACEUTICALS LLCInventors: Tao Tom Du, Chang Lee
-
Publication number: 20160045518Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.Type: ApplicationFiled: July 28, 2015Publication date: February 18, 2016Inventors: Ranjan Dohil, John Bastian, Seema S. Aceves, Elaine Phillips, Malcolm Hill
-
Publication number: 20160045519Abstract: The present invention relates to use of a composition for maintenance of bone and/or cartilage health or prevention, alleviation and/or treatment of bone and/or cartilage disorders.Type: ApplicationFiled: April 2, 2014Publication date: February 18, 2016Inventors: Marie Noelle HORCAJADA, Fanny MEMBREZ, Elizabeth OFFORD CAVIN
-
Publication number: 20160045520Abstract: The present invention has for object the use of minocycline or its equivalent forms, or any form of tetracycline in combination with acycloguanosine or any equivalent form (antiviral), atorvastatin or any equivalent form (lipophilic statins) and vitamin D3 (pro hormone) for the preparation of a single compound addressed to treatment of autoimmune type of rheumatoid arthritis in the three stages of development, whether it is active or quiescent phase or forms of diseases eziopatologicamente equivalent, but some degenerative. The efficacy of this combination has been proven by many studies on individual components.Type: ApplicationFiled: August 20, 2014Publication date: February 18, 2016Inventors: Fabrizio DE SILVESTRI, Edoardo ROMANI
-
Publication number: 20160045521Abstract: Aminobisphosphonate pamidronate (PAM) can control Epstein-Barr virus (EBV) associated disorders in humanized mice through a V?9V?2-T-cell dependent mechanism. This suggests a strong potential for a therapeutic approach using PAM to boost human V?9V?2-T-cell immunity against EBV associated disorders, such as the lymphoproliferative disease (LPD), posttransplant lymphoproliferative disorder (PLPD), Hodgkin's disease, Burkitt's lymphoma, and nasopharyngeal carcinoma (NPC).Type: ApplicationFiled: August 12, 2015Publication date: February 18, 2016Inventors: Wenwei Tu, Zheng Xiang, Yinping Liu
-
Publication number: 20160045522Abstract: This invention provides medicines and technology for use in treating cancer. The approach is to administer a hypoxia activated prodrug, followed by administration of another chemotherapeutic agent that is not a hypoxia activated prodrug. The median survival in pancreatic cancer patients can be extended by several months using such medicines and technology. This invention also provides methodology to assist the clinician in identifying subjects who will benefit most from the therapy. Drug combinations are provided to help the clinician manage side effects that may occur in the course of treatment.Type: ApplicationFiled: February 21, 2013Publication date: February 18, 2016Applicant: Threshold Pharmaceuticals, Inc.Inventor: Stewart Kroll
-
Publication number: 20160045523Abstract: A pharmaceutical formulation, comprising a phosphatidylcholine product of formula (I), wherein R1 is the residue of a saturated or unsaturated fatty acid with 12-24 carbon atoms, and R2 is the residue of a saturated or unsaturated fatty acid with 12-24 carbon atoms, and wherein the phosphatidylcholine product (PC) contains the following amounts of fatty acids: 55-72 linoleic acid; 10 18 palmitic acid; 07 15 oleic acid; 02 08 linolenic acid; 02 08 stearic acid, and at least one excipient for delayed release, can be used for the improved treatment of ulcerative colitis.Type: ApplicationFiled: March 25, 2014Publication date: February 18, 2016Inventor: Gerhard KEILHAUER
-
Publication number: 20160045524Abstract: A galactooligosaccharide composition comprising a mixture of disaccharides, trisaccharides, a tetrasaccharide and a pentasaccharide for use in preventing or treating cognitive dysfunction and/or emotional disturbances in neuropsychiatric illnesses or ageing.Type: ApplicationFiled: March 17, 2014Publication date: February 18, 2016Inventor: Georgios TZORTZIS
-
Publication number: 20160045525Abstract: The invention discloses sedoheptulose for use in the prevention or treatment of inflammation.Type: ApplicationFiled: March 21, 2014Publication date: February 18, 2016Applicant: MEDIZINISCHE UNIVERSITAT WIENInventors: Arvand Haschemi, Oswald Wagner, Csorsz Nagy, Rodrig Marculescu
-
Publication number: 20160045526Abstract: 2?-disubstituted substituted nucleoside derivatives of formula (I) and pharmaceutically acceptable salts thereof are disclosed: (1), wherein A is N3 or NH2 and X, Y, R1, R2, R3, R4, R5 and R18 are as defined herein. Compositions comprising at least one 2?-disubstituted nucleoside derivative, and methods of using the 2?-disubstituted nucleoside derivatives for treating or preventing HCV infection in a patient are disclosed.Type: ApplicationFiled: October 11, 2013Publication date: February 18, 2016Applicant: MERCK SHARP & DOHME CORP.Inventors: Vinay Girijavallabhan, Stephane Bogen, Weidong Pan, Qun Dang, Ian Davies
-
Publication number: 20160045527Abstract: This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from sleep apnea, including obstructive sleep apnea syndrome (OSAS). Treatment is effected by administering a carbonic anhydrase inhibitor to the patient in combination with an aldosterone antagonist. Formulations containing a therapeutically effective amount of a carbonic anhydrase inhibitor and a therapeutically effective amount of an aldosterone antagonist are provided as well.Type: ApplicationFiled: August 13, 2015Publication date: February 18, 2016Inventors: Charles H. Bowden, Craig Peterson
-
Publication number: 20160045528Abstract: Disclosed herein are a combination of compounds and methods of using the combination of compounds for ameliorating, treating and/or preventing a paramyxovirus viral infection.Type: ApplicationFiled: August 3, 2015Publication date: February 18, 2016Inventors: Lawrence M. Blatt, Leonid Beigelman, David Bernard Smith, Guangyi Wang
-
Publication number: 20160045529Abstract: The described herein is a pharmaceutical composition for use in humans or animals containing N-palmitoylethanolamide and Cytidinediphosphocholine for the treatment of pathologies of the Central Nervous System of a traumatic, vascular, degenerative nature associated with neurodegeneration. The pharmaceutical composition containing palmitoylethanolamide (PEA) and Cytidinediphosphocholine (CDP-Choline or Citicoline), possibly with the addition of an antioxidant compound such as for example a polyphenol, alpha-lipoic acid or L-acetylcysteine.Type: ApplicationFiled: August 12, 2015Publication date: February 18, 2016Applicant: EPITECH GROUP S.R.L.Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Salvatore Cuzzocrea
-
Publication number: 20160045530Abstract: Provided is a novel combination therapy using an FTD/TPI combination drug which exhibits remarkable antitumor effects, and few side effects. An antitumor agent is characterized in that one cycle of an administration schedule, in which, in a period of 14 days, the FTD/TPI combination drug is administered on days 1 to 5, and CPT-11 is administered on day 1, is repeated at least once.Type: ApplicationFiled: March 27, 2014Publication date: February 18, 2016Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventor: Hiroyuki OKABE
-
Publication number: 20160045531Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.Type: ApplicationFiled: March 14, 2014Publication date: February 18, 2016Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott Richard Daigle, Roy MacFarlane Pollock
-
Publication number: 20160045532Abstract: Disclosed herein are methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a chemotherapeutic agent. Example disclosed methods reduce cardiotoxicity of a chemotherapeutic agent. Also disclosed are methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a chemotherapeutic agent. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the chemotherapeutic agent.Type: ApplicationFiled: March 13, 2014Publication date: February 18, 2016Inventors: David D. Roberts, David R. Soto Pantoja
-
Publication number: 20160045533Abstract: The present application relates to compositions comprising selenium compounds, such as 5?-Methylselenoadenosine, Se-Adenosyl-L-homocysteine, Gamma-glutamyl-methylseleno-cysteine, a compound of Formula (I), Formula (II), or Formula (III), and combinations thereof, and methods of using the same for modulating glucose metabolism in a subject.Type: ApplicationFiled: September 15, 2015Publication date: February 18, 2016Inventors: Ronan Power, Zi-Jian Lan
-
Publication number: 20160045534Abstract: A method of synergistically attenuating platelet hyperactivation and enhancing connective tissue regeneration including administering an aqueous parenteral solution to a subject, the aqueous parenteral solution containing a glycosaminoglycan having a weight average molecular weight from about 1.5 to about 6000 kD, and a concentration of about 0.1% to about 7.0%, a neutral colloidal polysaccharide having a weight average molecular weight of about 20 to about 75 kD, and a concentration of about 1.0% to about 25%, and an isomaltose oligomer having a weight average molecular weight of about 0.4 to about 8 kD, and a concentration of about 0.3% to about 25%.Type: ApplicationFiled: October 28, 2015Publication date: February 18, 2016Applicant: Glenpharma ABInventors: Peter Byron Buckley, Konrad Messmer, Mark William Phillips
-
Publication number: 20160045535Abstract: The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by Neisseria meningitidis especially of serogroup B. To this end, the invention in particular provides a lipooligosaccharide (LOS) of N. meningitidis in particular constituted by a lipid A, an inner core, an ? chain of L6 or L8 type, in which the heptose II residue of the inner core bears in position O-3 and in position O-6 or O-7 a phosphoethanolamine (PEA) substituent, and also to the construction of the strain of N. meningitidis that is capable of expressing such an LOS. The invention also relates to a strain of N. meningitidis of serogroup A that bears a lipooligosaccharide (LOS) in particular constituted by a lipid A, an inner core, an ? chain of L6 type, in which the heptose II residue of the inner core bears in position O-3 a phosphoethanolamine (PEA) substituent and does not bear a PEA substituent in positions O-6 and O-7.Type: ApplicationFiled: August 5, 2015Publication date: February 18, 2016Applicant: Sanofi Pasteur SAInventors: Noelle Mistretta, Monique Moreau, Genevieve Renauld-Mongenie, Bachra Rokbi
-
Publication number: 20160045536Abstract: A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient.Type: ApplicationFiled: October 27, 2015Publication date: February 18, 2016Applicant: CLS PHARMACEUTICALS, INC.Inventors: C. Michael SAMSON, Bo LIANG, Joseph A. CAPRIOTTI
-
Publication number: 20160045537Abstract: The present invention generally relates to compositions and methods for treatment of skin and/or other soft tissues that are infected with bacteria such as Staphylococcus aureus, and/or other infectious organisms. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a site of infection, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.Type: ApplicationFiled: October 27, 2015Publication date: February 18, 2016Applicant: Transdermal Biotechnology, Inc.Inventor: Nicholas V. Perricone
-
Publication number: 20160045538Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of acne or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with acne, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.Type: ApplicationFiled: October 27, 2015Publication date: February 18, 2016Applicant: Transdermal Biotechnology, Inc.Inventor: Nicholas V. Perricone
-
Publication number: 20160045539Abstract: The present invention generally relates to compositions and methods for treatment of various inflammatory diseases, such as inflammatory dermatoses and other conditions, e.g., using nitric oxide. Examples of such dermatoses include psoriasis, atopic dermatitis, and contact dermatitis. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto an inflammation site, or other suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.Type: ApplicationFiled: October 27, 2015Publication date: February 18, 2016Applicant: Transdermal Biotechnology, Inc.Inventor: Nicholas V. Perricone
-
Publication number: 20160045540Abstract: The present invention generally relates to compositions and methods for transdermal drug delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.Type: ApplicationFiled: October 27, 2015Publication date: February 18, 2016Applicant: Transdermal Biotechnology, Inc.Inventor: Nicholas V. Perricone
-
Publication number: 20160045541Abstract: The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth or repair. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location where muscle growth is desired, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.Type: ApplicationFiled: October 27, 2015Publication date: February 18, 2016Applicant: Transdermal Biotechnology, Inc.Inventor: Nicholas V. Perricone
-
Publication number: 20160045542Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of osteoporosis or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto a suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.Type: ApplicationFiled: October 27, 2015Publication date: February 18, 2016Applicant: Transdermal Biotechnology, Inc.Inventor: Nicholas V. Perricone
-
Publication number: 20160045543Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of neuropathic pain or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with neuropathic pain, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.Type: ApplicationFiled: October 27, 2015Publication date: February 18, 2016Applicant: Transdermal Biotechnology, Inc.Inventor: Nicholas V. Perricone
-
Publication number: 20160045544Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of cancer or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.Type: ApplicationFiled: October 27, 2015Publication date: February 18, 2016Applicant: Transdermal Biotechnology, Inc.Inventor: Nicholas V. Perricone
-
Publication number: 20160045545Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of sexual dysfunction. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the penis, vulva, or other suitable portion of the skin. The composition can also be applied to a mucosal surface in some instances.Type: ApplicationFiled: October 27, 2015Publication date: February 18, 2016Applicant: Transdermal Biotechnology, Inc.Inventor: Nicholas V. Perricone
-
Publication number: 20160045546Abstract: Provided are compositions containing amorphous calcium carbonate (ACC), and at least one phosphorylated peptide which stabilizes the amorphous form of said calcium carbonate. Particularly, the peptide can be selected from crustacean proteins, also provided by the invention, namely GAP65, GAP22, GAP21, and GAP12 (also indicated herein as GAP10). The compositions are useful in pharmaceutical and nutraceutical formulations.Type: ApplicationFiled: June 19, 2015Publication date: February 18, 2016Applicant: AMORPHICAL LTD.Inventors: Shmuel BENTOV, Amir SAGI, Amir BERMAN, Assaf SHECHTER
-
Publication number: 20160045547Abstract: Provided is a method for preventing or treating sinusitis by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers. The ORP water solution can be administered alone or, e.g., in combination with one or more additional therapeutic agents.Type: ApplicationFiled: October 27, 2015Publication date: February 18, 2016Applicant: OCULUS INNOVATIVE SCIENCES, INC.Inventor: Hojabr ALIMI
-
Publication number: 20160045548Abstract: The present invention discloses a use of dendritic killer cell population for manufacturing medication. The dendritic killer cell population is generated by culturing peripheral blood mononuclear cells with effective amounts of various cytokines for an appropriate time period, and the conserved cytokine is IL-15. Meanwhile a pharmaceutical composition comprises the above dendritic killer cell population for treating cancers is also disclosed in the present invention.Type: ApplicationFiled: October 28, 2015Publication date: February 18, 2016Inventor: Jan Mou Lee
-
Publication number: 20160045549Abstract: Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include applying to macrophages in cell culture an agent that causes upregulation of ABCA1 transporter protein, and administering the macrophages to a subject. The agents include, without limitation, LXR agonists. Administration routes can include, without limitation, intraocular, periocular, and systemic administration.Type: ApplicationFiled: October 30, 2015Publication date: February 18, 2016Inventor: Rajendra S. Apte
-
Publication number: 20160045550Abstract: A method of expanding double negative T cells in culture is described. The method comprises (a) providing a starting sample comprising DN T cells or precursors thereof; (b) substantially depleting CD8+ and CD4+ T cells from the starting sample; (c) culturing the sample from step (b) with an immobilized T cell mitogen in a culture medium comprising an agent that can stimulate DN T cell growth (d) washing the cells obtained in step (c) and resuspending in a culture medium comprising the agent without the T cell mitogen; and (e) washing the cells obtained in step (d) and resuspending in a culture medium comprising the agent and a soluble T cell mitogen. The DN T cells obtained by the method are useful in a variety of applications including the treatment of cancer, infectious diseases, graft versus host disease and autoimmune disease.Type: ApplicationFiled: March 31, 2015Publication date: February 18, 2016Inventors: Li Zhang, Mei Han, Pouneh Dokouhaki
-
Publication number: 20160045551Abstract: The present invention provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to immunoresponsive cells bearing antigen receptors, which can be chimeric antigen receptors (CARS), which express introduced ligands for immunomodulatory molecules. In particular embodiments, engineered immunoresponsive cells are antigen-directed and resist immunosuppression and/or have enhances immune-activating properties.Type: ApplicationFiled: August 25, 2015Publication date: February 18, 2016Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Renier J. Brentjens, Hollie J. Jackson
-
Publication number: 20160045552Abstract: Methods and compositions for treating diseased or damaged tissue, such as Inflammatory Bowel Disease, e.g., Ulcerative Colitis, include tissue regeneration using stem cells or tissue grafts which stimulate stem cell migration to the damaged tissue. The tissue grafts can be extracellular matrix (ECM) material, such as tissue-specific extracellular matrix (TS-ECM). The methods can also include mucosal resection of the damaged or diseased tissue prior to placement of the graft.Type: ApplicationFiled: April 8, 2014Publication date: February 18, 2016Applicants: Asana Medical, Inc., University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Marc Ramer, Stephen F. Badylak, Timothy Keane
-
Publication number: 20160045553Abstract: The invention provides a cell delivery medium comprising a liquid phase, wherein the liquid phase comprises (i) one or more cells suspended within the liquid phase and (ii) a plurality of polymer gel particulates. Methods of producing the cell delivery systems are also provided.Type: ApplicationFiled: March 10, 2014Publication date: February 18, 2016Inventors: Liam GROVER, Fotios SPYROPOULOS, Jennifer PAXTON
-
Publication number: 20160045554Abstract: The present invention relates to methods for generating mature insulin-producing ?-like cells comprising the steps: (a) isolating, purifying and/or enriching ?-cell progenitor cells from a population of cells; (b) differentiation of the ?-cell progenitor cells into immature insulin-producing ?-like cells; and (c) maturation of the immature insulin-producing ?-like cells into mature insulin-producing ?-like cells, comprising exposing the immature insulin-producing ?-like cells to calcitriol or an analogue thereof. More particularly, the present invention relates to methods for generating mature insulin-producing ?-like cells for use in treating diabetes.Type: ApplicationFiled: March 28, 2014Publication date: February 18, 2016Applicant: The University of Western AustraliaInventor: Fang-Xu Jiang